Back to Clinical Trials

Tirzepatide

Mounjaro, Zepbound, LY3298176

Quick Stats

Studies 183

Trials 100

Overview Studies Clinical Trials

Recruiting PHASE4 INTERVENTIONAL NCT05553093

Effects of Tirzepatide and Insulin Glargine on Glucolipid Metabolism and Brain Function in Patients With Type 2 Diabetes

View on ClinicalTrials.gov Updated Dec 15, 2025

Brief Summary

The effects of Tirzepatide and Insulin Glargine on glucose and lipid metabolism and inflammation in patients with type 2 diabetes mellitus. Effects of Tirzepatide on the occurrence and development of cognitive impairment in diabetic patients and its associated pattern of changes in brain neural network characteristics.

Detailed Description

The aim of the study is to investigate the effects of Tirzepatide and Insulin Glargine on glucose and lipid metabolism and inflammation in patients with type 2 diabetes mellitus. Meanwhile, this study will evaluate the effects of Tirzepatide on the development of cognitive impairment and its associated pattern of changes in neural network characteristics in diabetic patients.

Interventions

Name: Tirzepatide

Type: DRUG

Description: Tirzepatide ih qw

Name: Insulin Glargine

Type: DRUG

Description: 6 IU ih qd

Primary Outcomes

Measure: blood sugar changes

TimeFrame: 40 weeks

Description: Effects of Tirzepatide and Insulin Glargine on blood sugar changes in Patients With Type 2 Diabetes Mellitus

Measure: blood lipid changes

TimeFrame: 40 weeks

Description: Effects of Tirzepatide and Insulin Glargine on blood lipid changes in Patients With Type 2 Diabetes Mellitus

Measure: Brain function

TimeFrame: 40 weeks

Description: Effects of Tirzepatide and Insulin Glargine on brain function through VBM and ASL-fMRI in Patients With Type 2 Diabetes Mellitus.

Trial Information

NCT ID

NCT05553093

Status

Recruiting

Study Type

INTERVENTIONAL

Phases

PHASE4

Sponsor

Nanjing First Hospital, Nanjing Medical University

Last Updated

December 15, 2025